Results 181 to 190 of about 68,214 (292)

The MSA Atrophy Index (MSA‐AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Reliable biomarkers are essential for tracking disease progression and advancing treatments for multiple system atrophy (MSA). In this study, we propose the MSA Atrophy Index (MSA‐AI), a novel composite volumetric measure to distinguish MSA from related disorders and monitor disease progression. Methods Seventeen participants with an
Paula Trujillo, Kilian Hett, Amy Cooper, Amy E. Brown, Jessica Iregui, Manus J. Donahue, M. Erik Landman, Italo Biaggioni, Margaret Bradbury, Cynthia Wong, David Stamler, Daniel O. Claassen   +11 more
wiley   +1 more source

Private equity investment, exit strategy and IPO performance: evidence from Indian IPOs

, 2018
Supriya Katti, B.V. Phani, N.A. Kunal
openalex   +1 more source

Mechanical Thrombectomy for TRACE‐III‐Eligible Patients With Ischemic Stroke: A Multicenter Retrospective Study Compared to TRACE‐III and TIMELESS Trials

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The results of the TRACE‐III trial demonstrated that tenecteplase (TNK) might be comparable to TNK combined with mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke within 4.5 to 24 h of onset, as tested in the TIMELESS trial.
Chongyang Huang, Yanru Liu, Jiangang Zhang, Sheng Guan, Tao Quan, Zhen Chen, Xiaojie Fu, Sen Wei, Kaihao Han, Xiaoan Zhou, Chengcheng Zhu, Edgar Samaniego, Yueqi Zhu, Haowen Xu   +13 more
wiley   +1 more source

STRATEGY OF THE CHOICE OF THE OPTIMUM RATIO OF SIZE OF THE YIELD OF MILK AND EXIT OF THE ISSUE

, 2018
В. М. Гукежев, M. S. Gabayev, Zh. H. Zhashuyev, М. А. Губжоков   +3 more
openalex   +2 more sources

Continuous Monitoring of Bladder Dysfunction in People With Multiple Sclerosis: Wearables for the Bladder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Bladder dysfunction affects over 85% of people with multiple sclerosis (PwMS), yet current assessment methods are limited to periodic in‐clinic evaluations or subjective patient reports, failing to capture real‐world symptom fluctuations.
Valerie J. Block, Shane Poole, Leah McIntyre, Nikki Sisodia, Chelyn Park, Gabby Joseph, Michelle E. Van Kuiken, Anne M. Suskind, Riley Bove   +8 more
wiley   +1 more source

Replication Data for Exit Strategy: Career Concerns and Revolving Doors in Congress TABLE A5.do

, 2019
Hye Young You, Michael E. Shepherd
openalex   +2 more sources

Planning phase-2 for the endoscopic units in Northern Italy after COVID-19 lockdown: an exit strategy with a lot of critical issues and a few opportunities.

, 2020
Gianpiero Manes, Alessandro Repici, Franco Radaelli, Simone Saibeni, Cristina Bezzio, Matteo Colombo, Fábio Pace   +6 more
openalex   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad, Taimoon Rasheed, Momina Riaz Siddiqui, Hamza Hamid, Marwah Bintay Khalid, Haroon Shabbir, Besher Shami, Abdullah, Syed Ijlal Ahmed   +8 more
wiley   +1 more source

National COVID-19 lockdown exit strategies need to pay more attention to community engagement and workplace safety. [PDF]

J Glob Health, 2020
Cresswell K, Dhami S, Sheikh A.
europepmc   +1 more source

European Debt Crisis and Fiscal Exit Strategies

, 2010
Catherine Mathieu, Henri Sterdyniak
openalex   +1 more source